uniQure N.V. (NASDAQ:QURE) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of uniQure N.V. (NASDAQ:QURE) have received a consensus rating of “Moderate Buy” from the seventeen brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $53.25.

A number of research analysts have recently commented on the stock. William Blair raised shares of uniQure to a “strong-buy” rating in a research note on Wednesday, September 23rd. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, September 29th. The Goldman Sachs Group dropped their price target on shares of uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. UBS Group reaffirmed a “buy” rating and set a $48.00 price target (up from $27.00) on shares of uniQure in a research report on Thursday, October 15th. Finally, Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th.

Hedge Funds Weigh In On uniQure

A number of large investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP bought a new position in uniQure during the 2nd quarter worth $15,254. IFP Advisors Inc raised its holdings in shares of uniQure by 39.8% during the second quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 791 shares during the last quarter. Fulton Bank N.A. bought a new stake in shares of uniQure during the second quarter valued at approximately $220,000. Activest Wealth Management bought a new position in uniQure in the 3rd quarter worth approximately $121,000. Finally, Syon Capital LLC bought a new stake in uniQure during the 2nd quarter valued at $279,000. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

Shares of QURE opened at $22.43 on Wednesday. The company has a 50-day simple moving average of $36.88 and a 200-day simple moving average of $34.13. uniQure has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.56 billion, a PE ratio of -5.59 and a beta of 1.06.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The business had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. During the same quarter in the prior year, the firm earned ($0.69) earnings per share. Equities research analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.